Geron to re-initiate phase-I trial of human embryonic stem cell product GRNOPC1 to treat spinal cord injury
Geron Corporation announced the company’s plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.
[Read the full article here]Related News:
First Clinical Trial Using Embryonic Stem Cell Therapy For Spinal Cord Injury Patients
FDA Approves Embryonic Stem Cell-Based Therapy For Patients With Acute Spinal Cord Injury
Hard To Treat Diseases : Human Clinical Trial of Embryonic Stem Cell-Based Therapy